Im Jinwoo J, Shachter Ross D, Oliva Elizabeth M, Henderson Patricia T, Paik Meenah C, Trafton Jodie A
Center for Health Care Evaluation, Department of Veterans Affairs, Menlo Park, CA, USA,
J Gen Intern Med. 2015 Jul;30(7):979-91. doi: 10.1007/s11606-015-3220-y. Epub 2015 Feb 19.
Patients receiving opioid therapy are at elevated risk of attempting suicide. Guidelines recommend practices to mitigate risk, but it is not known whether these are effective.
Our aim was to examine associations between the receipt of guideline-recommended care for opioid therapy and risk of suicide attempt.
DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective analysis of administrative data for all Veteran patients prescribed any short-acting opioids on a chronic basis or any long-acting opioids from the Veterans Health Administration during fiscal year 2010.
Multivariate, mixed-effects logistic regression analyses were conducted to define the associations between the risk of suicide attempt and receipt of guideline-recommended care at the individual level and rates of use of recommended care at the facility level, while accounting for patient risk factors.
At the individual level, having a mood disorder was highly associated with suicide attempts (odds ratios [ORs] = 3.5, 3.9; 95% confidence intervals [CIs] = 3.3-3.9, 3.3-4.6 for chronic short-acting and long-acting groups, respectively). At the facility level, patients on opioid therapy within the facilities ordering more drug screens were associated with decreased risk of suicide attempt (ORs = 0.2, 0.3; CIs = 0.1-0.3, 0.2-0.6 for chronic short-acting and long-acting groups, respectively). In addition, patients on long-acting opioid therapy within the facilities providing more follow-up after new prescriptions were associated with decreased risk of suicide attempt (OR = 0.2, CI = 0.0-0.7), and patients on long-acting opioid therapy within the facilities having higher sedative co-prescription rates were associated with increased risk of suicide attempt (OR = 20.3, CI = 1.1-382.2).
Encouraging facilities to make more consistent use of drug screening, provide follow-up within 4 weeks for patients initiating new opioid prescriptions, and avoid sedative co-prescription in combination with long-acting opioids may help prevent suicide attempts. Some clinicians may selectively employ guideline-recommended practices with at-risk patients.
接受阿片类药物治疗的患者自杀未遂风险升高。指南推荐了降低风险的措施,但尚不清楚这些措施是否有效。
我们的目的是研究接受阿片类药物治疗的指南推荐护理与自杀未遂风险之间的关联。
设计、设置和参与者:这是一项对2010财年退伍军人健康管理局开具任何长效阿片类药物或任何短效阿片类药物的所有退伍军人患者行政数据的回顾性分析。
进行多变量、混合效应逻辑回归分析,以确定个体层面自杀未遂风险与接受指南推荐护理之间的关联,以及机构层面推荐护理的使用比率,同时考虑患者风险因素。
在个体层面,患有情绪障碍与自杀未遂高度相关(慢性短效和长效组的比值比[ORs]分别为3.5、3.9;95%置信区间[CIs]分别为3.3 - 3.9、3.3 - 4.6)。在机构层面,在开具更多药物筛查的机构接受阿片类药物治疗的患者自杀未遂风险降低(慢性短效和长效组的ORs分别为0.2、0.3;CIs分别为0.1 - 0.3、0.2 - 0.6)。此外,在新处方后提供更多随访的机构接受长效阿片类药物治疗的患者自杀未遂风险降低(OR = 0.2,CI = 0.0 - 0.7),而在镇静剂联合处方率较高的机构接受长效阿片类药物治疗的患者自杀未遂风险增加(OR = 20.3,CI = 1.1 - 382.2)。
鼓励机构更持续地进行药物筛查,对开始新阿片类药物处方的患者在4周内进行随访,并避免将镇静剂与长效阿片类药物联合处方,可能有助于预防自杀未遂。一些临床医生可能会对高危患者选择性地采用指南推荐的措施。